CSF3 and breast carcinoma: The authors reported that the percentage of breast cancer patients in high-risk chemotherapy regimens receiving G-CSF as primary prophylaxis was greater in patients with commercial insurance (33.4%) than in patients with Medicare (17.8%) or Medicaid (24.4%) even though preauthorization is not required by Medicare [7].